Characteristics of the study sample at baseline
| Group 1# | Group 2¶ | Total | p-value | |
| Patients | 16 | 16 | 32 | |
| Sex | 0.144 | |||
| Female | 8 (50) | 4 (25) | 12 (37.5) | |
| Male | 8 (50) | 12 (75) | 20 (62.5) | |
| Age years | 8.0±1.6 | 7.8±1.8 | 7.9±1.7 | 0.977 |
| Atopy | 14 (87.5) | 13 (81.3) | 27 (84.4) | 1.000 |
| Medication use | ||||
| SABA | 14 (87.5) | 15 (93.8) | 29 (90.6) | 1.000 |
| LABA | 2 (12.5) | 2 (12.5) | 4 (12.5) | 1.000 |
| ICS | 11 (68.8) | 15 (93.8) | 26 (81.3) | 0.172 |
| NCS | 9 (56.3) | 5 (31.3) | 14 (43.8) | 0.143 |
| LTRA | 2 (12.5) | 2 (12.5) | 4 (12.5) | 1.000 |
Data are presented as n, n (%) or mean±sd, unless otherwise stated. SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; NCS: nasal corticosteroid; LTRA: leukotriene receptor antagonist. #: Diskus use in the morning and Autohaler in the evening; ¶: Autohaler use in the morning and Diskus in the evening.